Search review questions

Clinical improvement: discharged alive ( · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

Clinical worsening: new need for invasive mechanical ventilation or death · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

Serious adverse events ( · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

Adverse events (any grade) ( · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

Hospital‐acquired infections ( · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

Invasive fungal infections ( · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings…

Improvement of clinical status: all initial symptoms resolved (asymptomatic) at day 14 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§

Improvement of clinical status: time to symptom resolution · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§

QoL (physical component) at up to 28 days, measured on the PROMIS Global‐10 scale and normalized to values from 16.2, low QoL, to 67.2, maximum QoL · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§

QoL (mental component) at up to 28 days, measured on the PROMIS Global‐10 scale and normalized to values from 21.2, low QoL, to 67.6, maximum QoL · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§

Serious adverse events during the trial period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§

Any adverse events during the trial period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§

Viral clearance at day 7 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§

Worsening of clinical status: participants with new need for invasive mechanical ventilation or death at day 28 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings…

Improvement of clinical status: participants discharged alive at day 28 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings…

QoL at longest · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings…

Serious adverse events during the trial period · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings…

Any adverse events during the trial period · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings…

Viral clearance at day 7 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings…

All‐cause mortality at day 28 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§

Worsening of clinical status: admission to hospital or death within 28 days · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§

Outcomes(Time frame of absolute effects) · hospitalised people with confirmed SARS‐CoV‐2 infection

All‐cause mortality (up to day 28) · hospitalised people with confirmed SARS‐CoV‐2 infection

All‐cause mortality (up to day 60) · hospitalised people with confirmed SARS‐CoV‐2 infection

Improvement in clinical status: discharged alive or hospitalised, but no longer requiring ongoing medical care (up to day 28) · hospitalised people with confirmed SARS‐CoV‐2 infection

Worsening of clinical status: new need for invasive mechanical ventilation or death (at day 28) · hospitalised people with confirmed SARS‐CoV‐2 infection

Adverse events (any grade) · hospitalised people with confirmed SARS‐CoV‐2 infection

Serious adverse events · hospitalised people with confirmed SARS‐CoV‐2 infection

Secondary infection · hospitalised people with confirmed SARS‐CoV‐2 infection

All‐cause mortality (at day 28) · symptomatic people with COVID‐19

All‐cause admission to hospital or death (before hospital admission) · symptomatic people with COVID‐19

Symptom resolution · symptomatic people with COVID‐19

Quality of life (at longest · symptomatic people with COVID‐19

Serious adverse events (during study period) · symptomatic people with COVID‐19

Any adverse events (during study period) · symptomatic people with COVID‐19

Suicide or suicide attempt (at longest · symptomatic people with COVID‐19

Complete haematological response at 12 months · adults with newly diagnosed warm AIHA

Frequency of adverse events at two, six and 12 months · adults with newly diagnosed warm AIHA

Partial haematological response at 12 months · adults with newly diagnosed warm AIHA

Overall survival at six and 12 months · adults with newly diagnosed warm AIHA

Relapse‐free survival at six and 12 months · adults with newly diagnosed warm AIHA

RBC transfusion requirement after treatment at 12 months · adults with newly diagnosed warm AIHA

QOL as measured by validated instruments at 12 months · adults with newly diagnosed warm AIHA

Overall survival ( · people with relapsed or refractory DLBCL

Quality of life ( · people with relapsed or refractory DLBCL

Any adverse events ( · people with relapsed or refractory DLBCL

Any serious adverse events ( · people with relapsed or refractory DLBCL

Cytokine release syndrome ( · people with relapsed or refractory DLBCL